Allosteric modulation of 5-HT1A receptors by zinc: Binding studies

Neuropharmacology

Volumn 56, Issue 2, 2009, Pages 455-462

  Barrondo, Sergio ^a   Sallés, Joan ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Allosteric ternary complex model; Zinc ion binding site

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CYSTEINE; DIETHYL PYROCARBONATE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HISTIDINE; N ETHYLMALEIMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RADIOLIGAND; SEROTONIN 1A RECEPTOR; ZINC;

ALLOSTERISM; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN CORTEX; CONTROLLED STUDY; DISSOCIATION CONSTANT; HIPPOCAMPUS; LIGAND BINDING; MALE; NERVE ENDING; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ALLOSTERIC REGULATION; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL MEMBRANE; CEREBRAL CORTEX; CHLORIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INHIBITORY CONCENTRATION 50; MALE; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; PIPERAZINES; PROTEIN BINDING; PYRIDINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; TRITIUM; ZINC COMPOUNDS;

EID: 58549090142     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.09.018     Document Type: Article

References (47)

1. 35S]GTPyS binding in rat hippocampal membranes. Eur. J. Pharmacol. 343 (1998) 303-312
2. Alper R.H., and Nelson D.L. Inactivation of 5-HT1A serotonin receptors in hippocampal and cortical homogenates. Eur. J. Pharmacol. 390 (2000) 67-73
3. 2+ from brain tissue during activity. Nature 308 (1984) 734-736
4. Christopoulos A., and Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54 (2002) 323-374
5. Christopoulos A., and Mitchelson F. Application of an allosteric ternary complex model to the technique of pharmacological resultant analysis. J. Pharm. Pharmacol. 49 (1997) 781-786
6. Christopoulos A. Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol. Sci. 19 (1998) 351-357
7. Christopoulos A., Parsons A.M., Lew M.J., and El-Fakahany E.E. The assessment of antagonist potency under conditions of transient response kinetics. Eur. J. Pharmacol. 382 (1999) 217-227
8. Colvin R.A. pH dependence and compartmentalization of zinc transported across plasma membrane of rat cortical neurons. Am. J. Physiol. Cell. Physiol. 282 (2002) C317-C329
9. Ehlert F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33 (1988) 187-194
10. Fowler C.B., Pogozheva I.D., Levine H., and Mosberg H.I. Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. Biochemistry 43 (2004) 8700-8710
11. Frederickson C.J. Neurobiology of zinc and zinc-containing neurons. Int. Rev. Neurobiol. 31 (1989) 145-238
12. Frederickson C.J., Hernandez M.D., and McGinty J.F. Translocation of Zinc may contribute to seizure-induced death of neurons. Brain Res. 480 (1989) 317-321
13. Garro M.A., López de Jesús M., Ruiz de Azúa I., Callado L.F., Meana J.J., and Sallés J. Regulation of phospholipase C-beta activity by muscarinic acetylcholine and 5-HT2 receptors in crude and synaptosomal membranes from human cerebral cortex. Neuropharmacology 40 (2001) 686-695
14. 35S]GTPγS binding to cortical membranes from post-mortem human brain. Eur. J. Pharmacol. 390 (2000) 25-36
15. Hansen C.R., Malecha M., Mackenzie T.B., and Kroll J. Copper and zinc deficiencies in association with depression and neurological findings. Biol. Psychiatry 18 (1983) 395-401
16. Holst B., Elling C.E., and Schwartz T.W. Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors. J. Biol. Chem. 277 (2002) 47662-47670
17. Horstman D.A., Brandon S., Wilson A.L., Guyer C.A., Cragoe E.J., and Limbird L.E. An aspartate conserved among G-protein receptors confers allosteric regulation of alpha-2-adrenergic receptors by sodium. J. Biol. Chem. 265 (1990) 21590-21595
18. Howell G.A., Welch M.G., and Frederickson C.J. Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 308 (1984) 736-738
19. Kay A.R. Imaging synaptic zinc: promises and perils. Trends Neurosci. 29 (2006) 200-206
20. Kenakin T., Jenkinson S., and Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther. 319 (2006) 710-723
21. 3H]WAY-100635, a novel 5-HT1A receptor antagonist to rat brain. J. Neurochem. 64 (1995) 2716-2726
22. Laube B., Kuhse J., Rundstrom N., Kirsch J., Scmieden V., and Betz H. Modulation by zinc ions of native rat and recombinant human inhibitory glycine receptors. J. Physiol. (Lond.) 483 Pt 3 (1995) 613-619
23. Lazareno S., and Birdsall N.M.J. Detection, quantitation and verification of allosteric interactions of agents with labelled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48 (1995) 362-378
24. Leonard N.J., McDonald J.J., and Reochmann M.E. Reaction of pyrocarbonate with nucleic acid components. Proc. Natl. Acad. Sci. U.S.A. 67 (1970) 93-98
25. Lew M.J., and Angus J.A. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol. Sci. 16 (1995) 328-337
26. 2+-site engineering. Eur. J. Pharmacol. 479 (2003) 187-197
27. López-Rodríguez M.L., Vicente B., Deupi X., Barrondo S., Olivilla M., Morcillo M.J., Behamú B., Ballesteros J.A., Sallés J., and Pardo L. Design, synthesis and pharmacological evaluation of 5-HT1A receptor ligands to explore the three-dimensional structure of the receptor. Mol. Pharmacol. 62 (2002) 15-21
28. 2+ from presynaptic terminals into postsynaptic hippocampal neurons after physiological stimulation. J. Neurophysiol. 86 (2001) 2597-2604
29. 2+ binding site on the dopamine D2 receptor. Biochem. Biophys. Res. Commun. 339 (2006) 873-879
30. Maes M., D́Haese P.C., Scharpe S., D́Hondt P., Cosyns P., and De Broe M.E. Hypozincemia in depresión. J. Affect. Disord. 31 (1994) 135-140
31. May L.T., Leach K., Sexton P.M., and Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 1-51
32. McLoughlin I.J., and Hodge J.S. Zinc in depressive disorder. Acta Psychiatr. Scand. 82 (1990) 451-453
33. 35S]-GTPyS binding in rat brain: absence of regional differences in coupling efficiency. J. Pharmacol. Exp. Ther. 292 (2000) 684-691
34. Neve K.A., Cumbay M.G., Thompson K.R., Yang R., Buck D.C., Watts V.J., DuRand C.J., and Teeter M.M. Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor. Mol. Pharmacol. 60 (2001) 373-381
35. Nowak G., Legutko B., Szewczyk B., Wieronska J.M., Branski P., PaluchaPilc A., Sadlik K., and Piekoszewski W. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res. Bull. 61 (2003) 159-164
36. Nowak G., Siwek M., Dudek D., Zieba A., and Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol. J. Pharmacol. 55 (2003) 1143-1147
37. Pompeiano M., Palacios J.M., and Mengod G. Distribution and cellular localization of Messenger-RNA coding for 5-HT1A receptor in the rat brain. Correlation with receptor binding. J. Neurosci. 12 (1992) 440-453
38. Schetz J.A., and Sibley D.R. Zinc allosterically modulates antagonist binding to cloned D1A and D2L dopamine receptors. J. Neurochem. 68 (1997) 1990-1997
39. Schetz J.A., Cho A., and Sibley D.R. Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. J. Pharmacol. Exp. Ther. 289 (1999) 956-964
40. Schetz J.A., and Sibley D.R. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation. J. Pharmacol. Exp. Ther. 296 (2001) 359-363
41. Solomons N.W. Zinc and copper. In: Shils M.E., and Young V.R. (Eds). Modern Nutrition in Health and Disease (1988), Lea and Fibiger, Philadelphia 238-262
42. 2+. Mol. Pharmacol. 61 (2002) 65-72
43. 2+ on the beta-2 adrenergic receptor. J. Biol. Chem. 278 (2003) 352-356
44. Takeda A. Movement of zinc and its functional significance in the brain. Brain Res. Rev. 34 (2000) 137-148
45. 2+ spillover modulates heterosynaptic NMDA receptor activation in hippocampal CA3 circuits. J. Cell Biol. 158 (2002) 215-220
46. Vallee B.L., and Falchuck K.H. The biochemical basis of zinc physiology. Physiol. Rev. 73 (1993) 79-118
47. 2+ antagonize NMDA and GABA responses of hippocampal neurons. Nature 328 (1987) 640-643